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Abstract 
BACKGROUND: Management of diarrhea-predominant irritable bowel syndrome (IBS-D) 
is generally based on patient-reported symptoms, yet there is limited information about 
symptom severity. 
METHODS: We conducted two web-based surveys of HCPs and patients from Australia, 
Canada, and Europe.  We analyzed patient characteristics and attitudes by IBS-D severity 
using a composite of four variables: worst abdominal pain, IBS symptom frequency, Bristol 
Stool Form Scale, and quality of life (QoL).   
RESULTS: Of 679 HCP respondents, one-third routinely classify patients by severity.  The 
patient survey was completed by 513 patients with mild (26%), moderate (33%), and severe 
(41%) IBS-D, as classified using the composite scale.  Age, sex, and treatment satisfaction 
did not change with severity. Nineteen percent of patients classified with severe IBS-D 
agreed with the statement: “When my IBS is bad, I wish I was dead” vs. 4% and 7% of 
patients with mild and moderate IBS-D, respectively (P<0.05).  Significantly more patients 
classified with severe IBS-D reported use of both prescription and over-the-counter 
medications vs. mild IBS-D. 
CONCLUSIONS: Compared with milder symptoms, severe IBS-D was associated with 
increased medication use and a negative perspective of IBS-D.  This highlights the need for a 
validated severity scale for use in research and clinical practice, to inform treatment 
decisions.  
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KEY SUMMARY 
 
SUMMARISE THE ESTABLISHED KNOWLEDGE ON THIS SUBJECT 
 The management of irritable bowel syndrome with diarrhea (IBS-D) is 
generally informed by patient-reported symptoms. 
 More severe IBS-D, based on patient-reported severity, is associated with 
worse health-related quality of life (QoL) and increased work and activity 
impairment, adverse food reactions, and healthcare resource use 
 Rome guidance advocates quantifying symptom severity, but there is 
limited data on the differences between mild and severe IBS 
 As more treatments become available for IBS, further guidance on severity 
is required to identify which patients are most likely to benefit from them 
WHAT ARE THE SIGNIFICANT AND/OR NEW FINDINGS OF THIS STUDY? 
 Primary care physicians and gastroenterologists had a similar approach to 
the assessment of IBS-D severity, but specialists more often used worst 
abdominal pain and Bristol stool form scale 
 Patients with severe IBS-D were more likely to have continuous symptoms 
and higher medication use than those with moderate or mild IBS-D  
 Severe IBS-D was associated with an increase in negative emotions and a 
greater desire to find a treatment that significantly improves QoL 
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 Development of a comprehensively designed and validated scale is 
warranted for the assessment of severity in IBS-D 
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INTRODUCTION  
Irritable bowel syndrome (IBS) is a chronic functional bowel disorder with a global 
prevalence of around 11% [1].  IBS is characterized by abdominal pain with altered bowel 
habits, such as a predominance of constipation (IBS-C), diarrhea (IBS-D), or a mixed pattern 
of both (IBS-M), as well as urgency and bloating [2, 3].  Prevalence of the IBS-C, IBS-D, and 
IBS-M subtypes has been reported as 35%, 40%, and 23%, respectively [1].  Symptoms vary 
from mild to severe and intermittent to continuous, with incidence of mild IBS reported 
estimated to be ~40%, moderate ~35%, and severe ~25%, based on patients self-perceived 
severity [4]. Patients who self-report severe IBS-D have been described as experiencing 
greater impairments in health-related quality of life (QoL), increased work and activity 
impairment, more adverse food reactions, and increased healthcare resource use compared to 
patients who self-report mild or moderate IBS-D [5-9].  
To date there is no established definition of severity for IBS.  The Rome IV diagnostic 
criteria do not classify patients according to IBS severity, but set out a multifactorial 
approach for the diagnosis of IBS based on symptoms, primarily abdominal pain and 
diarrhea. [2].  The Rome IV criteria state that IBS treatment should be dependent upon 
symptom type and severity [2] (for example, linaclotide is recommended for patients with 
moderate-to-severe IBS-C [10]); however, no validated scale is suggested to assess this, 
beyond those available for IBS as a whole, such as the Birmingham-IBS questionnaire, 
functional bowel disorder severity index, and the IBS symptom severity scale (IBS-SSS). 
These scales do not take into account the multifactorial diagnostic approach set out by the 
Rome IV criteria [4, 11-14] and are not specific to IBS-D or IBS-C.  Therefore, classification 
of IBS-D severity is dependent upon the type of scale used and whether the patient or 
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physician makes the severity definition, as well as variables such as symptom intensity, time 
of assessment, and degree of disability or impairment [15]. 
We conducted a study which surveyed: (i) patients receiving treatment for IBS-D and (ii) 
treating gastroenterologists and primary care physicians, to assess the health burden of IBS-D 
on patients and the attitudes and perspectives of treating HCPs towards IBS-D. Our primary 
analysis found that many patients are dissatisfied with their current treatment and feel under 
supported by their HCPs, whilst the physicians themselves find IBS-D to be a challenging 
condition to manage. One surprising finding of the study was that faecal urgency was 
reported as the most troublesome symptom rather than the characteristic diarrhea and 
abdominal pain.[16]   
The aim of this post hoc subanalysis was to evaluate HCPs’ attitudes towards the 
classification of severity in IBS-D based on the survey data and to evaluate symptom burden, 
medication consumption, and patients’ attitudes graded by severity, as defined using patient-
reported variables. 
MATERIALS AND METHODS 
The study was comprised of two web-based, self-administered surveys of (1) treating HCPs 
and (2) patients with IBS-D.  Detailed methodology of the surveys are described 
elsewhere.[16]  Each structured questionnaire was administered via market research panels 
provided by Survey Sampling International and included individuals from Australia, Canada, 
France, Germany, Italy, Spain, and the UK. 
The 40-minute HCP survey was completed between February and April 2016.  
Gastroenterologists and primary care physicians (PCPs) were included, with a target sample 
size of 45 of each HCP type per country.  HCPs were paid honoraria of up to $150 for 
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participating in the survey.  The analysis described here focuses on responses to questions 
around the assessment of IBS-D severity. 
The 30-minute patient survey was completed between January and February 2016.  The target 
sample size was 80 patients per country.  Patients with IBS-D opted-in to complete the survey 
via an email link; they received a small monetary compensation for their time.  The survey 
comprised 51 questions assessing patients’ attitudes towards their IBS and IBS treatments. 
Sample population 
For both surveys, individuals who were affiliated with a pharmaceutical company or who had 
participated in IBS market research within the 3 months prior to the study were excluded. 
For the HCP survey, those who met the following screening criteria were included in the 
analysis: 3–35 years’ experience in their role; consultant grade or equivalent 
(gastroenterologists only); consultations with patients with diagnosed IBS-D within 3 months 
prior to the survey; and prescribed medication or recommended over-the-counter treatments 
for patients with IBS-D. 
For the patient survey, those who met the following screening criteria were included: males 
and females aged 18–65 years; diagnosed with IBS-D by a doctor; symptoms of diarrhea and 
abdominal pain, discomfort, or spasm; symptoms present for >1 year and within the past 12 
months; currently using prescription or over-the-counter medications for IBS-D; had not had 
their gallbladder removed; and not diagnosed with gastrointestinal comorbidities including 
chronic constipation, inflammatory bowel disease, celiac disease, stomach cancer, 
diverticulitis, ulcerative colitis, Crohn’s disease, pancreatitis, and small intestinal 
inflammation.  Target maximum quotas were set for the proportion of female patients (70%) 
and the proportion of patients who had never seen a gastroenterologist for their IBS-D (40%). 
9 
 
Responses to statements 
HCPs’ and patients’ attitudes to statements were scored using a 7-point Likert scale 
(1=completely disagree; 4=neither agree nor disagree; 7=completely agree).  Participants who 
answered 6 (agree) or 7 were considered to agree with the statement; those who answered 
1 or 2 (disagree) were considered to disagree with the statement.  Participants with a score of 
3–5 were classed as neither agreeing nor disagreeing with the statement. 
Definition of IBS-D severity 
For the HCP survey, definitions of severity (mild, moderate, and severe) were provided to 
survey participants, as defined by the 2011 Rome Foundation Working Team report [4].  
Mild IBS-D was defined as mild or intermittent abdominal pain, little or no psychological 
distress, with occasional impact on activities.  Moderate IBS-D was defined as moderate or 
frequent abdominal pain, more psychological distress, with more frequent impact on 
activities.  Severe IBS-D was defined as very frequent or continuous abdominal pain, high 
psychological distress, with frequent or constant impact on activities.  The survey also 
captured the criteria that HCPs were currently using to assess IBS-D symptom severity. 
In the patient survey IBS-D severity was calculated using an algorithm comprising four 
variables chosen retrospectively to reflect the Rome IV diagnostic criteria [2], recent clinical 
trial data, and clinical experience.  Worst abdominal pain (WAP) scored from 0 (no pain) to 
10 (worst pain imaginable), frequency of IBS symptoms measured in days/month, stool 
consistency scored from BSFS 3 (stools which are like a sausage but with cracks on its 
surface) to 7 (watery stool with no solid pieces, entirely liquid), and a measure of QoL 
assessed according to patient responses to the single statement: “Having IBS stops me 
enjoying life”, scored on a 7-point Likert scale.  A symptom frequency score was created by 
taking the maximum number of days from four questions on average monthly frequency of 
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stomach pain and/or diarrhea symptoms.  The questions and response choices are listed in 
Supplementary Table 1.  
Symptom frequency, WAP, BSFS and QoL scores were grouped into high or low categories 
(and medium for QoL) selected on the judgement of the lead investigators and informed by 
prior experience in the therapeutic area. These categories were the basis of the algorithm used 
to stratify patients into groups of mild, moderate, or severe IBS-D as per Figure 1.   
Statistical analysis 
Anonymized patient responses were analyzed at the respondent record level and stratified by 
the mild/moderate/severe classification. Statistical analyses were performed on the 
differences between the three severity groups.  Two-tailed t-tests were performed for the 
means and proportions from independent groups (mild, moderate, severe IBS-D; HCPs and 
PCPs) to compare demographics, characteristics, and attitudes data at a 5% risk level, with 
P<0.05 denoting significance.  Analyses were completed in Microsoft Excel (Microsoft, 
Redmond, WA, USA). 
RESULTS 
HCP survey 
Of the 1,460 HCPs screened, 313 gastroenterologists and 366 PCPs were eligible for 
inclusion and completed the survey.  The demographics and caseloads of these HCPs are 
described elsewhere [17]. 
HCP classification of IBS-D severity 
Approximately one third each of PCPs (30%) and gastroenterologists (31%) reported that 
they routinely classify their IBS-D patients by severity (Table 1).  Using the severity 
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definitions provided, gastroenterologists estimated that 42% of their diagnosed or suspected 
IBS-D patients have mild, 41% have moderate, and 18% have severe IBS-D.  Similarly, PCPs 
estimated that 46%, 40%, and 14% of their diagnosed or suspected IBS-D patients have mild, 
moderate, and severe IBS-D, respectively. 
Very few of the HCPs who routinely assessed IBS-D severity reported using guidelines to 
make this classification (3% and 8% of PCPs and gastroenterologists, respectively).  In 
general, around half of the HCPs who classified patients by IBS-D severity reported that this 
was based on the frequency/duration of symptoms, type of symptoms, and/or impact on daily 
life (Table 1).  Of those HCPs who did not routinely classify their patients by severity in their 
day-to-day practice, impact on QoL, level of abdominal pain, number of symptomatic days in 
an average month, and frequency of diarrhea were the factors most likely to be used for this 
purpose (Figure 2 Supplementary Figure 1).  Compared to PCPs, gastroenterologists were 
more likely to use frequency of diarrhea, whether a patient responds to treatment, and stool 
consistency to make a severity assessment (Figure 2 Supplementary Figure 1). 
Use and awareness of the BSFS and WAP scale varied widely between the groups of HCPs: 
61% of PCPs reported a lack of awareness/use of the BSFS, compared to 28% of 
gastroenterologists (Figure 32).  Similarly, 63% of PCPs reported a lack of awareness/use of 
the WAP scale, compared to 48% of gastroenterologists (Figure 32). 
Patient survey 
Demographics and healthcare characteristics 
Overall, 8,627 patients were screened, of whom 513 were eligible and completed the survey; 
the mean age was 40.9 years and 70% were female [17].  All 513 patient responses were 
anonymized and assessed for severity, 193 patients (38%) had severe IBS-D, 158 (31%) had 
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moderate IBS-D, and 124 (24%) had mild IBS-D (Table 2).  In total, 38 patients (7%) did not 
meet the severity criteria and were excluded from the severity analysis, including patients 
who answered “prefer not to answer” on BSFS score and “0—no pain” for WAP score.  
Comorbidities were generally evenly distributed across all severity groups, although a 
significantly greater proportion of patients with severe IBS-D reported depression and 
fibromyalgia compared to patients with mild or moderate IBS-D (P<0.05 for both 
comparisons; Table 2).  Patients tended to have undergone several prior diagnostic tests, with 
a greater proportion of patients with severe IBS-D having had an endoscopy/colonoscopy 
(69%) compared to patients with mild (48%) or moderate (58%) IBS-D (P<0.05 for both 
comparisons; Table 2).  Age and sex were not associated with IBS-D severity. 
IBS symptom characteristics  
The mean duration of IBS symptoms for was 9.8 years without any significant difference in 
duration across severity groups (Supplementary Table 2).  The two most common reasons for 
patients having a first visit to an HCP were increasing frequency of symptoms and large 
impact on QoL for all severity groups (Supplementary Table 2). 
A greater proportion of patients with severe IBS-D reported continual symptoms over the 
3 months prior to the survey compared to those with mild or moderate IBS-D (P<0.05 for 
both comparisons; Figure 3a).  For individual IBS symptoms, a larger proportion of patients 
with severe IBS-D listed urgency as common, compared to patients with mild or moderate 
IBS-D (47% vs. 35% for mild and moderate; P<0.05 for both comparisons) and a larger 
proportion with severe IBS-D listed fecal incontinence as common, compared to mild or 
moderate IBS-D (22% vs. 16% and 13%, respectively; P<0.05 for severe vs. moderate 
groups; Supplementary Table 2).  Finally, patients with severe IBS-D were more likely to 
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report fecal urgency as the most troublesome symptom, compared to patients with mild or 
moderate IBS-D (34% vs. 23% and 20%, respectively; P<0.05 each; Figure 53b). 
Medication use 
Of the different types of medications used, patients with severe IBS-D were more likely to 
use antidiarrheals compared to patients with mild or moderate IBS-D (87% vs. 76% and 78%, 
respectively; P<0.05 each; Table 3).  A proportion of patients in all groups reported the use 
of codeine-based painkillers, analgesics, and antidepressants, including patients with only 
mild IBS-D (Table 3); however, antidepressant use was reported by a greater proportion of 
patients with severe vs. mild or moderate IBS-D (20% vs. 11% or 16%, respectively; P<0.05 
as compared to mild only).  Concurrent use of prescription and over-the-counter medications 
was reported in a greater proportion of patients with severe IBS-D compared to patients with 
mild or moderate IBS-D (36% vs. 24% or 29%, respectively; P<0.05 as compared to mild 
only; Table 3).  Patients with severe IBS-D were also more likely to take three or more types 
of treatment intermittently or every day compared to those with mild IBS-D (69% vs. 56%; 
P<0.05).  Treatment satisfaction for all medications considered was not found to be 
associated with IBS-D severity (data not shown). 
Patient attitudes 
Overall patient attitudes towards IBS-D are described in the initial overall report [17].  
Response frequencies on negative emotions were significantly higher in patients with severe 
IBS-D for all emotions, compared to mild or moderate IBS-D, whereas response frequencies 
on positive emotions such as feeling “in control” or “accepting” were generally lower for 
patients with severe IBS-D compared to mild or moderate IBS-D (10% vs. 40% and 20%; 
23% vs. 35% and 34%, respectively; Figure 4). 
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Compared to patients with mild or moderate IBS-D, there was a tendency for a significantly 
greater proportion of patients with severe IBS-D to report agreement with negative statements 
related to their IBS; over half of patients with severe IBS-D were constantly worried about 
when their symptoms would return, compared to patients with mild or moderate IBS-D (55% 
vs. 19% and 30%, respectively; P<0.05 each) (Supplementary Figure 2A).  Further, 19% of 
patients with severe IBS-D agreed with the statement: “When my IBS is bad, I wish I was 
dead”, compared to 4% of patients with mild IBS-D and 7% of patients with moderate IBS-D 
(P<0.05 for both comparisons).   
Similar severity associations were observed in terms of patients’ attitudes towards HCPs and 
services (Supplementary Figure 2B).  A significantly greater proportion of patients with 
severe IBS-D agreed with statements that there should be more services and education 
available for patients with IBS, compared to patients with mild or moderate IBS-D (59% vs. 
27% and 35%, respectively; P<0.05 each), and that IBS is a “last resort” diagnosis (31% vs. 
15% and 18%, respectively; P<0.05 each).   
Regarding current therapies, 62% of patients with severe IBS-D agreed with the statement: “I 
would use a daily treatment for the rest of my life if it prevented IBS symptoms”, compared 
to 26% of patients with mild IBS-D (P<0.05) and 49% of patients with moderate IBS-D 
(P<0.05; Supplementary Figure 2C).  Overall, 60% of patients with severe IBS-D would be 
willing to try anything to help manage their IBS, compared to 28% of patients with mild IBS-
D and 43% with moderate IBS-D (P<0.05 each).   
 
DISCUSSION 
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This post hoc analysis indicates that increasing severity of IBS-D was associated with 
increased medication use and a negative impact on patients’ attitudes towards the condition 
itself and HCPs, services, and available treatments.  In addition, we found that the majority of 
HCPs surveyed did not routinely assess severity in their patients with IBS.  There is therefore 
a need for a standardized, multidimensional scale to assess severity in IBS-D, including 
measures of self-reported outcomes covering health-related QoL, psychosocial factors, and 
burden of illness associated with IBS-D, particularly as new treatments emerge that are 
specific for this condition.  A more complete understanding of symptom severity could not 
only improve the management and treatment of IBS-D, but could also inform patient 
stratification during future clinical trials to assess efficacy and safety across severity 
subgroups.  One available method which could assist clinicians in monitoring symptoms is, 
the IBS-D daily symptom diary and event log, a patient-reported outcome measure designed 
to measure treatment benefit, which includes measures of patient impression of severity and 
change over time.[18-20] 
In those HCPs who did routinely assess severity, this was largely based on the 
frequency/duration of symptoms, type of symptom, and perceived impact on patients’ daily 
lives.  When directly questioned, similar criteria including abdominal pain, number of 
symptomatic days, and frequency of diarrhea were likely to be used by those HCPs who did 
not routinely assess severity in their day-to-day practice, factors which are included in the 
Rome IV diagnostic criteria for IBS [2].  It is particularly noteworthy, given that most IBS 
patients are managed in the community, that a large proportion of PCPs were found to be 
unaware of the BSFS and WAP scale.  Among PCPs and gastroenterologists, only half of 
those surveyed used either scale in their clinical practice, despite the inclusion of the BSFS in 
the Rome IV criteria [2].  Further, very few respondents indicated that they used guidelines in 
the assessment of severity, indicating that current IBS-D guidelines are inadequate in this 
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respect.  While various scales for the assessment of severity in IBS have been reported 
previously, such as the Birmingham-IBS questionnaire and IBS-SSS, these assessments are 
not specific to IBS-D [11-13].  
In the current analysis, we used a composite severity scale to define subgroups of patients 
with IBS-D.  This algorithm, although limited by the data already collected in the primary 
survey, was retrospectively designed to reflect the latest Rome IV diagnostic criteria [2], 
capturing information related to four key variables (abdominal pain, frequency of IBS 
symptoms, stool form, and QoL).  As such, this work was not powered to present a definitive 
research-oriented severity index, but rather to assess differences in physical symptoms, 
attitudes and behaviors in order to inform clinicians’ future management strategies according 
to IBS severity.  A prospectively developed severity index for IBS-D will require external 
validation for use in clinical practice [21, 22].  This validation should include validation of 
the content, construct, and criteria, as well as an assessment of the reliability and 
responsiveness of the index, with consideration given to the target sample numbers required a 
priori [23, 24]. 
IBS-D imposes a substantial burden on patients with the condition, who can experience 
troublesome symptoms, such as urgency, for long periods of time.  Patients also express high 
levels of dissatisfaction with available treatments, which demonstrates an unmet need for the 
satisfactory management of these patients.  This is important to note, as patient education has 
been shown to reduce IBS symptom severity [25, 26] and to improve QoL [26], suggesting 
that management of patients’ attitudes towards IBS will also help them manage their 
symptoms.  Indeed, we found that a greater proportion of patients classified with severe 
IBS-D agreed that more education should be available. 
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Rome IV criteria state that IBS treatment should be dependent upon symptom type and 
severity, with initial treatment involving reassurance and diet and lifestyle modifications [2].  
Other treatment options include opioid antagonists, bile acid sequestrants, probiotics, 
antibiotics, and 5-HT3 antagonists, yet prescription medications appear to be underutilized 
[27].  We observed in this study that while the majority of patients had received 
antidiarrheals, around 40% of patients with severe IBS-D were not taking any prescription 
medications but were relying on over-the-counter medications, despite over 60% of patients 
with severe IBS-D being willing to receive regular treatment. 
Classification of IBS-D severity is also crucial to understanding the natural history of the 
condition, and whether patients with mild IBS go on to develop more severe IBS or whether 
patients may fluctuate between severity grades.  A reliable method to classify IBS-D severity 
will also be of value for payers and regulatory agencies in order to indicate drugs based on 
IBS-D severity, such as alosetron, which is indicated by the FDA only for female patients 
with severe IBS-D [28]. 
These results should be interpreted in light of the study limitations.  As 60% of patients were 
required to have previously seen a gastroenterologist for their IBS-D, this patient population 
may have been skewed, leading to a higher estimate of patients suffering from severe IBS-D 
symptoms.  Likewise, the requirement for gastroenterologists to be consultant grade may 
have excluded the perspectives of younger HCPs.  In addition, the limitations of the survey 
itself include the use of a single question to assess troublesome symptoms (patients may have 
several highly troublesome symptoms), and also the lack of appropriate response options for 
certain questions.  Indeed, a proportion of patients with severe IBS-D selected their most 
troublesome symptom as “other” (i.e. not listed in this questionnaire).  In particular, the 
troublesome symptom question did not take into account the severity of individual symptoms.  
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Further, there may be inherent biases introduced by the use of the Likert format, such as 
acquiesce bias (the tendency for respondents to agree with statements) [29].  Finally, there are 
limitations to the severity algorithm utilized in this analysis.  We feel that the categories we 
selected to assess severity WAP, BSFS, symptom frequency and QoL adequately reflect the 
key factors we use to assess IBS-D in the clinic, however the depth of information available 
to us particularly within the QoL and symptom frequency categories was limited due to the 
retrospective development of the severity scale. This scale does not assess certain factors 
reported as important drivers of reduced QoL, such as abdominal distension or urgency [30]; 
this is also true of the IBS-SSS, which does not assess urgency and incontinence.  However, 
this scale was able to demonstrate some clear differences in patient characteristics and 
attitudes according to the level of IBS-D severity and therefore highlights the need for a 
validated scale. 
CONCLUSIONS 
This post hoc analysis demonstrated that patient characteristics and attitudes differ 
substantially according to the severity of their IBS-D symptoms.  This indicates a need for the 
development of a symptom severity index.  Further attention is warranted by the Rome IV 
Committees as part of their multi-axial work-up of patients with functional disorders [4].  We 
also identified a distinct need for improved pharmacological and supportive management of 
patients with IBS-D in order to reduce symptom burden, particularly in those with more 
severe IBS-D. 
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Tables 
Table 1.  Factors used by PCPs and gastroenterologists to classify patients with IBS-D by 
severity 
aBased on responses to the question: “Do you classify or group your diagnosed IBS-D 
patients by severity in your day-to-day practice?”  bBased on responses to the question: 
“Please describe below how you classify or group your diagnosed IBS-D patients by severity 
in your day-to-day practice”, (select all that apply) expressed as a proportion of those HCPs 
answering “yes” to the previous question. 
HCP, healthcare professional; IBS-D, irritable bowel syndrome with diarrhea; PCP, primary 
care physician. 
  
HCPs, n (%) 
PCPs 
(n=366) 
Gastroenterologists 
(n=313) 
Classifying patients by severitya 110 (30) 98 (31) 
Classification based on:b   
Frequency/duration of symptoms 59 (54) 48 (49) 
Impact on daily life 52 (47) 50 (51) 
Type of symptoms 51 (46) 46 (47) 
Intensity of symptoms 21 (19) 23 (23) 
Abdominal pain intensity scale 19 (17) 21 (21) 
Guidelines 3 (3) 8 (8) 
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Table 2.  Demographics and health characteristics by IBS-D severity 
 Mild IBS-D 
(n=124) 
Moderate IBS-D 
(n=158) 
Severe IBS-D 
(n=193) 
Female, n (%) 81 (65) 109 (69) 143 (74) 
Mean age, years (SD) 40.4 (10.9) 40.5 (11.2) 42.0 (12.1) 
Most common comorbidities, n (%)a,b 
Anxiety 42 (34) 60 (38) 73 (38) 
Depression 26 (21) 35 (22) 65 (34)*† 
Migraine 31 (25) 41 (26) 55 (28) 
Gastric reflux 23 (19) 38 (24) 39 (20) 
Lactose intolerance 11 (9) 23 (15) 30 (16) 
Fibromyalgia 3 (2) 5 (3) 22 (11)*† 
Diarrhea due to bacterial 
infection 
13 (10) 9 (6) 10 (5) 
Diagnostic testing history, n (%)c,d    
Blood tests 94 (76) 121 (77) 158 (82) 
Stool test 72 (58) 95 (60) 128 (66) 
Endoscopy/colonoscopy 59 (48) 91 (58) 134 (69)*† 
Food allergy tests 42 (34) 56 (35) 88 (46) 
*P<0.05 vs. patients with mild IBS-D; †P<0.05 vs. patients with moderate IBS-D. 
aBased on responses to the question: “Which of the following conditions, if any, have you 
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been diagnosed with by a doctor?”  bReported in ≥10% of patients.  cBased on responses to 
the question: “Which of the following tests have been carried out since you first experienced 
symptoms of IBS?”  dReported in ≥20% of patients. 
IBS, irritable bowel syndrome; IBS-D, irritable bowel syndrome with diarrhea; SD, standard 
deviation. 
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Table 4 3.  Medication use by IBS-D severity 
n, % 
Mild IBS-D 
(n=124) 
Moderate IBS-D 
(n=158) 
Severe IBS-D 
(n=193) 
Types of medication used over the past 12 monthsa  
Antidiarrheal 94 (76) 124 (78) 167 (87)*† 
Antispasmodic 71 (57) 99 (63) 112 (58) 
Analgesic 17 (14) 27 (17) 33 (17) 
Codeine-based painkiller 18 (15) 28 (18) 43 (22) 
Antidepressant 14 (11) 25 (16) 38 (20)* 
Other 9 (7) 11 (7) 15 (8) 
Current medication useb    
OTC medication only 59 (48) 66 (42) 75 (39) 
Prescription and OTC 
medication 
30 (24) 46 (29) 69 (36)* 
Prescription medication only 35 (28) 46 (29) 49 (25) 
*P<0.05 vs. patients with mild IBS-D; †P<0.05 vs. patients with moderate IBS-D. 
aBased on responses to the question: “Which of the following have you taken in the past 12 
months for your IBS?”  bBased on responses to the question: “Do you take either of the 
following to help manage your IBS?” 
IBS, irritable bowel syndrome; IBS-D, irritable bowel syndrome with diarrhea; OTC, over-
the-counter. 
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Figure legends 
Figure 1.  Criteria for the determination of IBS-D severity by worst abdominal pain, 
frequency of symptoms, Bristol Stool Form Scale, and quality of life.  Cut-offs for severity 
levels were arbitrary and based on clinical experience; frequency was based on the number of 
days with IBS symptoms.  BSFS, Bristol Stool Form Scale; IBS-D, irritable bowel syndrome 
with diarrhea; QoL, quality of life; WAP, worst abdominal pain. 
Figure 32.  Use of the Bristol Stool Form Scale and worst abdominal pain scale in the 
management of patients with IBS-D.  Based on responses to the question: “At what point, if 
at all, do you use the following scales in managing your IBS-D patients?”  (a) P<0.05 for 
PCPs vs. gastroenterologists unaware of the BSFS, only using the BSFS at initial assessment 
with patient, and using the BSFS at each consultation with patient before and after diagnosis.  
(b) P<0.05 for PCPs vs. gastroenterologists unaware of the WAP scale, aware of the WAP 
scale but not using, and using the WAP scale at each consultation with patient before and 
after diagnosis.  BSFS, Bristol Stool Form Scale; Gastro, gastroenterologist; HCP, healthcare 
professional; IBS-D, irritable bowel syndrome with diarrhea; PCP, primary care physician; 
WAP, worst abdominal pain. 
Figure 43.  Symptom patterns and most troublesome symptoms by IBS-D severity.  
a. Symptom patterns over the past 3 months by IBS-D severity.  P<0.05 for all comparisons 
(mild vs. severe and moderate vs. severe; continual and intermittent).  Based on responses to 
the question: “Which best describes the pattern of your IBS symptoms over the past 3 
months?”  aDefined as experiencing some IBS symptoms every day.  bDefined as having 
some days without any IBS symptoms.  IBS, irritable bowel syndrome; IBS-D, irritable 
bowel syndrome with diarrhea. 
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b.  Most troublesome symptoms currently experienced by IBS-D severity.  Based on the first 
selected response to the question: “Which of the symptoms you currently experience trouble 
you the most?” (bloating was not included as a potential response).  *P<0.05.  IBS-D, 
irritable bowel syndrome with diarrhea. 
Figure 6 4.  Patients’ feelings about having IBS by IBS-D severity.  Based on responses to 
the question: “How do you currently feel about having IBS?”  (a) Negative emotions 
associated with IBS.  (b) Positive emotions associated with IBS.  *P<0.05.  IBS, irritable 
bowel syndrome; IBS-D, irritable bowel syndrome with diarrhea. 
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Figure 1.  Criteria for the determination of IBS-D severity by worst abdominal pain, 
frequency of symptoms, Bristol Stool Form Scale, and quality of life.  Cut-offs for severity 
levels were arbitrary and based on clinical experience; frequency was based on the number of 
days with IBS symptoms.  BSFS, Bristol Stool Form Scale; IBS-D, irritable bowel syndrome 
with diarrhea; QoL, quality of life; WAP, worst abdominal pain. 
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Figure 32.  Use of the Bristol Stool Form Scale and worst abdominal pain scale in the 
management of patients with IBS-D.  Based on responses to the question: “At what point, if 
at all, do you use the following scales in managing your IBS-D patients?”  (a) P<0.05 for 
PCPs vs. gastroenterologists unaware of the BSFS, only using the BSFS at initial assessment 
with patient, and using the BSFS at each consultation with patient before and after diagnosis.  
(b) P<0.05 for PCPs vs. gastroenterologists unaware of the WAP scale, aware of the WAP 
scale but not using, and using the WAP scale at each consultation with patient before and 
after diagnosis.  BSFS, Bristol Stool Form Scale; Gastro, gastroenterologist; HCP, healthcare 
professional; IBS-D, irritable bowel syndrome with diarrhea; PCP, primary care physician; 
WAP, worst abdominal pain. 
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Figure 43 Symptom patterns and most troublesome symptoms by IBS-D severity.  
(a) Symptom patterns over the past 3 months by IBS-D severity.  P<0.05 for all comparisons 
(mild vs. severe and moderate vs. severe; continual and intermittent).  Based on responses to 
the question: “Which best describes the pattern of your IBS symptoms over the past 3 
months?”  aDefined as experiencing some IBS symptoms every day.  bDefined as having 
some days without any IBS symptoms.  IBS, irritable bowel syndrome; IBS-D, irritable 
bowel syndrome with diarrhea. 
(b) Most troublesome symptoms currently experienced by IBS-D severity.  Based on the first 
selected response to the question: “Which of the symptoms you currently experience trouble 
you the most?” (bloating was not included as a potential response).  *P<0.05.  IBS-D, 
irritable bowel syndrome with diarrhea. 
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Figure 6 4.  Patients’ feelings about having IBS by IBS-D severity.  Based on responses to 
the question: “How do you currently feel about having IBS?”  (a) Negative emotions 
associated with IBS.  (b) Positive emotions associated with IBS.  *P<0.05.  IBS, irritable 
bowel syndrome; IBS-D, irritable bowel syndrome with diarrhea. 
 
